• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Argenx Se ADR (NQ: ARGX )

    586.30 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Argenx Se ADR

    < Previous 1 2 3 Next >
    argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
    From argenx SE
    Via GlobeNewswire
    argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
    From argenx SE
    Via GlobeNewswire
    argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
    From argenx SE
    Via GlobeNewswire
    argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
    From argenx SE
    Via GlobeNewswire
    argenx to Present at Upcoming Investor Conferences
    From argenx SE
    Via GlobeNewswire
    argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
    From argenx SE
    Via GlobeNewswire
    argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
    From argenx SE
    Via GlobeNewswire
    argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
    From argenx SE
    Via GlobeNewswire
    Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
    From Zai Lab Limited
    Via Business Wire
    argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
    From argenx SE
    Via GlobeNewswire
    argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
    From argenx SE
    Via GlobeNewswire
    argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
    From argenx SE
    Via GlobeNewswire
    argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
    From argenx SE
    Via GlobeNewswire
    argenx Reports First Quarter 2024 Financial Results and Provides Business Update
    From argenx SE
    Via GlobeNewswire
    argenx announces results of Annual General Meeting of Shareholders
    From argenx SE
    Via GlobeNewswire
    argenx to Present at BofA Securities 2024 Health Care Conference
    From argenx SE
    Via GlobeNewswire
    argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
    From argenx SE
    Via GlobeNewswire
    argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
    From argenx SE
    Via GlobeNewswire
    argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
    From argenx SE
    Via GlobeNewswire
    argenx Announces Annual General Meeting of Shareholders on May 7, 2024
    From argenx SE
    Via GlobeNewswire
    argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
    From argenx SE
    Via GlobeNewswire
    argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
    From argenx SE
    Via GlobeNewswire
    argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
    From argenx SE
    Via GlobeNewswire
    argenx to Present at Upcoming Investor Conferences
    From argenx SE
    Via GlobeNewswire
    argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
    From argenx SE
    Via GlobeNewswire
    argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
    From argenx SE
    Via GlobeNewswire
    5 medical stocks growing earnings by triple digits
    There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning 
    Via MarketBeat
    Topics Economy
    Exposures Economy
    argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
    From argenx SE
    Via GlobeNewswire
    argenx Highlights 2024 Strategic Priorities
    From argenx SE
    Via GlobeNewswire
    argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
    From argenx SE
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.